Back to journals
Academic Journal

Journal of Psychiatric Research

17 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 17 psychedelic papers Blossom tracks from Journal of Psychiatric Research line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Journal of Psychiatric Research carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

4papers published in 2021

+300% vs 2020

9 published by 2021

Browse papers→

Don't read as the journal's total output: only the 17 of 17 tracked psychedelic papers from Journal of Psychiatric Research with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Journal of Psychiatric Research publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
16
Suicidality
11
Anxiety Disorders
8
Safety & Risk Management
5
PTSD
3
Bipolar Disorder
3
Addiction & Substance Use
2
Adolescents
2
Other
13

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Journal of Psychiatric Research cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Ketamine
10
MDMA
3
Psilocybin
3
Esketamine
2

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Journal of Psychiatric Research has 17 tracked papers indexed in Blossom (2014–2026) from 133 authors, most often covering Ketamine, MDMA and Psilocybin, across Depressive Disorders, Suicidality and Treatment-Resistant Depression (TRD).

Published Papers

Open Accessindividual

Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE study

This post-hoc analysis (n=128) of the French real-world ESKALE study found that intranasal esketamine produced a rapid and steadily increasing antidepressant response in patients with treatment-resistant depression over four weeks (response rate rising from 19% at week one to 47% at week four), and that experiencing dissociation during the first week of treatment may be an early indicator of a positive response.

Published
Journal
Journal of Psychiatric Research
Authors
Samalin, L., Rothärmel, M., Mekaoui, L., Sauvaget, A., Wicart, C., Gaudre-Wattine, E., Cohignac, V., Malatesta, A., Dupin, J.
Paywallindividual

MDMA-Assisted Therapy for Major Depressive Disorder: A Seven-Month Follow-Up Proof of Principle Trial

This long-term follow-up (n=12) of participants with moderate-to-severe major depressive disorder who received MDMA-assisted therapy (two dosing sessions integrated with nine psychotherapy sessions) found significant reductions in depression severity and functional impairment at seven months compared to baseline, with improvements maintained from the post-treatment assessment and no increases in suicidal ideation.

Published
Journal
Journal of Psychiatric Research
Authors
Kvam, T. M., Goksøyr, I. W., Rog, J., van de Vooren, I. T. J., Stewart, L. H., Autran, I., Berthold-Losleben, M., Mørch-Johnsen, L., Holst, R., Røssberg, J. I., Clausen, I., Andreassen, O. A.
Paywallindividual

The Impact of Antidepressant Discontinuation Prior to Treatment with Psilocybin for Treatment-Resistant Depression

This post hoc analysis (n=233) of a Phase II RCT investigates the impact of recent antidepressant discontinuation (n=156) on the efficacy of psilocybin in treating treatment-resistant depression (TRD). The study compares outcomes between participants who discontinued antidepressants during screening and those who entered the trial free of these medications, finding no significant relationship between antidepressant discontinuation and worsening depression severity or compromised psilocybin treatment efficacy.

Published
Journal
Journal of Psychiatric Research
Authors
Marwood, L., Croal, M., Mistry, S., Simmons, H., Tsai, J., Young, M. B., Goodwin, G. M.
Paywallindividual

Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results

This double-blind, randomised study (n=27) assessed the antidepressant effects of a novel oral prolonged-release formulation of racemic ketamine (KET01) in TRD patients as add-on therapy. Patients received either 160 mg/day or 240 mg/day KET01 or placebo for 14 days, with the primary endpoint being the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to day 15. Results suggest a positive trend towards antidepressant efficacy with 240 mg/day KET01.

Published
Journal
Journal of Psychiatric Research
Authors
Colla, M., Offenhammer, B., Scheerer, H., Kronenberg, G., Vetter, S., Mutschler, J., Mikoteit, T., Bankwitz, A., Adank, A., Schaekel, L., Eicher, C., Brühl, A. B., Seifritz, E.
Paywallindividual

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder

This open-label study (n=12) of patients suffering from Body dysmorphic disorder (BDD), an obsessive preoccupation with misperceptions of appearance, finds that psilocybin (25mg) plus psychological support (6 sessions) resulted in a response (>30% decrease in BDD-YBOCS) in 58% of participants. Secondary measures such as negative affect, disability, and conviction of belief also significantly decreased.

Published
Journal
Journal of Psychiatric Research
Authors
Feusner, J. D., Wheaton, M. G., Gomez, G. J., Cornejo, G., Naraindas, A. M., Hellerstein, D. J., Schneider, F.
Paywallmeta

Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis

This meta-analysis (2022) assessed the effectiveness of ketamine for treatment-resistant depression (TRD) using real-world data. While the mean antidepressant effect of ketamine was found to be significant, there are high levels of variability between patients. Treatment effects were found to be similar following repeated treatments.

Published
Journal
Journal of Psychiatric Research
Authors
Alnefeesi, Y., Chen-Li, D., Jawad, M. Y., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Gill, H., Teopiz, K. M., Cao, B., Lee, Y., McIntyre, R. S., Rosenblat, J. D., Ho, R.

Quick Facts

Papers Indexed
17
h-Index
172
Open Access
No
Publisher
Elsevier
Country
United Kingdom
Website
Visit